USCOM LIMITED — Regulatory Filings 2014

Sep 11, 2014

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

USCOM Part of World Sepsis Day in London

Friday 12th of September 2014: Uscom (ASX code: UCM) is pleased to announce the presentation of the BUSH protocol and other applications of the USCOM device in sepsis and septic shock at the World Sepsis Day symposium at the King’s College, London on World Sepsis Day.

World Sepsis Day is on the 13[th] September and is an initiative of the Global Sepsis Alliance, an organisation committed to the support of caregivers around the world as they seek to better understand and combat sepsis. As part of the World Sepsis Day Professor Brendan Smith from Australia has been invited to join with Professor Joe Carcillo from Children's Hospital Pittsburgh, USA and Dr Akash Deep from King's College in London to present at the King's College symposium in London on sepsis in children. Each of these presenters uses USCOM to manage sepsis in children.

Professor Brendan Smith from Australia will summarise results from his 6 year study of management outcomes of sepsis patients using USCOM in his BUSH protocol which has resulted in a reduction of mortality from the global average of 30-35% to 7%. Professor Smith’s pioneering research in regional NSW to improve management of sepsis and septic shock, using the Australian invented USCOM, is creating waves worldwide. Professor Smith and his team are at the forefront of the medical defense against this global epidemic. Professor Smith said, “there are no two ways about it, the USCOM device is helping us save lives daily.”

Dr Deep, Director of the Paediatric ICU at Kings College London said “USCOM has changed the way I look at the cardiovascular system of my patients, and has now been established as the standard of care.”

Executive Chairman of Uscom, Dr Rob Phillips said, “Sepsis is a global medical emergency which may kill one third of our friends and family, from newborns, children, in pregnancy, adults and the elderly. We developed USCOM to make a difference and it is changing the way we approach this dangerous disease, and it is saving lives. Professor Smith’s research demonstrated that if the BUSH protocol using USCOM was introduced in Australia there was a predicted saving of 8,237 Australian lives and more than $1billion over the last 6 years. USCOM is an important medical innovation in the fight against sepsis making a significant health economic contribution to health care.”

Uscom manufactures and markets the USCOM 1A and the Uscom BP+, both premium cardiovascular devices which are changing the way we diagnose and treat cardiovascular diseases, including hypertension, heart failure and sepsis, and improving guidance of fluid, inotropes and vasoactive therapies.

Uscom will provide access to the proceedings when they become available on the website www.uscom.com.au.

References:

1. The Lancet Infectious Diseases. For sepsis, the drugs don't work. Lancet Infect Dis 2012; 12: 89.

2. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet 2010; 376: 1339-1346.

3. Smith BE, Phillips RA, Madigan V, West MJ. Decreased Mortality, Morbidity and Emergency Transport in Septic Shock; A New Protocol Based on Advanced Noinvasive Haemodynamics (USCOM) and Early Antibiotics. Crit Care Med 2012; 40(12):1023. doi: 10.1097/01.ccm.0000424114.76434.7a

4. Yealy DM, Kellum JA, Huang DT, and the ProCESS Investigators. A Randomized Trial of Protocol-Based Care for Early Septic Shock. New Engl J Med 2014; DOI: 10.1056/NEJMoa1401602

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

==> picture [57 x 49] intentionally omitted <==

M A R K E T A N N O U N C E M E N T

About Uscom

Uscom Limited is an ASX listed cardiovascular medical device company. Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, the USCOM 1A and the BP+. The devices are both clinically validated with FDA, CE and TGA regulatory approval, and are currently being marketed into global distribution networks.

The USCOM 1A is a simple, cost-effective and non-invasive device that measures heart function, detects abnormalities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anesthesia, and is the device of choice for management of adult and paediatric sepsis, heart failure, and for the guidance of fluid therapy.

The Uscom BP+ is a supra systolic Central Blood Pressure monitor and replaces older and more widespread BP sub systolic Blood Pressure monitoring technology. Central Blood Pressure is becoming the new standard of care measurement in hypertension and heart failure. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, cardiology, intensive care, general practice and home care.

For more information, please visit: www.uscom.com.au

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Catherine Officer Company Secretary secretary@uscom.com.au